P2X7 受体在 COVID-19 发病机制中的潜在作用：新的治疗靶点？
The potential involvement of P2X7 receptor in COVID-19 pathogenesis: A new therapeutic target?
机构信息
Laboratório de Toxoplasmose e outras Protozooses, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
出版信息
Scand J Immunol. 2021 Feb;93(2):e12960. doi: 10.1111/sji.12960. Epub 2020 Sep 8.
Abstract
Coronavirus disease 2019 (COVID-19) pathogenesis remains under investigation. Growing evidence indicates the establishment of a hyperinflammatory response, characterized by sustained production of cytokines, such as IL-1β. The release and maturation of this cytokine are dependent on the activation of a catalytic multiprotein complex, known as "inflammasome". The most investigated is the NLRP3 inflammasome, which can be activated by various stimuli, such as the recognition of extracellular ATP by the P2X7 receptor. Based on the recent literature, we present evidence that supports the idea that the P2X7R/NLRP3 axis may be involved in the immune dysregulation caused by the SARS-CoV-2 infection.
摘要
新型冠状病毒病 2019（COVID-19）的发病机制仍在研究中。越来越多的证据表明，过度炎症反应的建立，其特征是细胞因子如 IL-1β的持续产生。这种细胞因子的释放和成熟依赖于一种称为“炎性体”的催化多蛋白复合物的激活。研究最多的是 NLRP3 炎性体，它可以被各种刺激激活，如 P2X7 受体识别细胞外 ATP。根据最近的文献，我们提出了证据支持这样一种观点，即 P2X7R/NLRP3 轴可能参与了由 SARS-CoV-2 感染引起的免疫失调。
相似文献
1
The potential involvement of P2X7 receptor in COVID-19 pathogenesis: A new therapeutic target?P2X7 受体在 COVID-19 发病机制中的潜在作用：新的治疗靶点？
Scand J Immunol. 2021 Feb;93(2):e12960. doi: 10.1111/sji.12960. Epub 2020 Sep 8.
2
TLR agonists stimulate Nlrp3-dependent IL-1β production independently of the purinergic P2X7 receptor in dendritic cells and in vivo.TLR 激动剂在树突状细胞和体内中独立于嘌呤能 P2X7 受体刺激 Nlrp3 依赖性的 IL-1β 产生。
J Immunol. 2013 Jan 1;190(1):334-9. doi: 10.4049/jimmunol.1202737. Epub 2012 Dec 7.
3
Soluble P2X7 Receptor Is Elevated in the Plasma of COVID-19 Patients and Correlates With Disease Severity.可溶性 P2X7 受体在 COVID-19 患者的血浆中升高，并与疾病严重程度相关。
Front Immunol. 2022 May 18;13:894470. doi: 10.3389/fimmu.2022.894470. eCollection 2022.
4
The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection.嘌呤能受体 P2X7 和 NLRP3 炎性小体是可药物治疗的宿主因子，是 SARS-CoV-2 感染所必需的。
Front Immunol. 2023 Oct 18;14:1270081. doi: 10.3389/fimmu.2023.1270081. eCollection 2023.
5
The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sjögren's syndrome.P2X7 受体-炎性小体复合物在原发性干燥综合征的炎症反应调节中起作用。
J Intern Med. 2013 Nov;274(5):480-9. doi: 10.1111/joim.12115. Epub 2013 Aug 17.
6
Potentiation of hepatic stellate cell activation by extracellular ATP is dependent on P2X7R-mediated NLRP3 inflammasome activation.细胞外ATP对肝星状细胞激活的增强作用依赖于P2X7R介导的NLRP3炎性小体激活。
Pharmacol Res. 2017 Mar;117:82-93. doi: 10.1016/j.phrs.2016.11.040. Epub 2016 Dec 8.
7
P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy.P2X7受体拮抗作用可防止唾液腺上皮细胞释放白细胞介素-1β，并减轻自身免疫性外分泌病小鼠模型中的炎症反应。
J Biol Chem. 2017 Oct 6;292(40):16626-16637. doi: 10.1074/jbc.M117.790741. Epub 2017 Aug 10.
8
A Dual Role for P2X7 Receptor during Porphyromonas gingivalis Infection.牙龈卟啉单胞菌感染期间P2X7受体的双重作用
J Dent Res. 2015 Sep;94(9):1233-42. doi: 10.1177/0022034515593465. Epub 2015 Jul 7.
9
Paxillin mediates ATP-induced activation of P2X7 receptor and NLRP3 inflammasome.桩蛋白介导ATP诱导的P2X7受体和NLRP3炎性小体激活。
BMC Biol. 2020 Nov 26;18(1):182. doi: 10.1186/s12915-020-00918-w.
10
The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies.NLRP3 炎性小体与 COVID-19：激活、发病机制和治疗策略。
Cytokine Growth Factor Rev. 2021 Oct;61:2-15. doi: 10.1016/j.cytogfr.2021.06.002. Epub 2021 Jun 18.
引用本文的文献
1
Env from EIAV vaccine delicately regulates NLRP3 activation via attenuating NLRP3-NEK7 interaction.来自马传染性贫血病毒疫苗的Env通过减弱NLRP3与NEK7的相互作用来精细调节NLRP3激活。
PLoS Pathog. 2025 Jun 16;21(6):e1012772. doi: 10.1371/journal.ppat.1012772. eCollection 2025 Jun.
2
The role of the P2X7 receptor in inactivated SARS-CoV-2-induced lung injury.P2X7受体在灭活的严重急性呼吸综合征冠状病毒2诱导的肺损伤中的作用
Purinergic Signal. 2025 Jun;21(3):465-483. doi: 10.1007/s11302-024-10062-7. Epub 2024 Nov 28.
3
Changes in Phenotypic and Molecular Features of Naïve and Central Memory T Helper Cell Subsets following SARS-CoV-2 Vaccination.SARS-CoV-2疫苗接种后初始和中枢记忆性T辅助细胞亚群的表型和分子特征变化
Vaccines (Basel). 2024 Sep 11;12(9):1040. doi: 10.3390/vaccines12091040.
4
Genetic Polymorphisms of P2RX7 but Not of ADORA2A Are Associated with the Severity of SARS-CoV-2 Infection.P2RX7 基因多态性而非 ADORA2A 与 SARS-CoV-2 感染的严重程度相关。
Int J Mol Sci. 2024 Jun 2;25(11):6135. doi: 10.3390/ijms25116135.
5
Implications of COVID-19 in Parkinson's disease: the purinergic system in a therapeutic-target perspective to diminish neurodegeneration.新型冠状病毒肺炎对帕金森病的影响：从治疗靶点角度看嘌呤能系统对减少神经退行性变的作用。
Purinergic Signal. 2024 Oct;20(5):487-507. doi: 10.1007/s11302-024-09998-7. Epub 2024 Mar 9.
6
Pharmacological interaction and immune response of purinergic receptors in therapeutic modulation.嘌呤能受体在治疗调节中的药物相互作用和免疫反应。
Purinergic Signal. 2024 Aug;20(4):321-343. doi: 10.1007/s11302-023-09966-7. Epub 2023 Oct 16.
7
The shed P2X7 receptor is an index of adverse clinical outcome in COVID-19 patients.膜 P2X7 受体是 COVID-19 患者不良临床结局的指标。
Front Immunol. 2023 May 5;14:1182454. doi: 10.3389/fimmu.2023.1182454. eCollection 2023.
8
Folic Acid and Leucovorin Have Potential to Prevent SARS-CoV-2-Virus Internalization by Interacting with S-Glycoprotein/Neuropilin-1 Receptor Complex.叶酸和甲酰四氢叶酸可能通过与 S-糖蛋白/神经纤毛蛋白-1 受体复合物相互作用来预防 SARS-CoV-2 病毒的内化。
Molecules. 2023 Mar 1;28(5):2294. doi: 10.3390/molecules28052294.
9
Synthesis, Biological Evaluation and Molecular Modeling Studies of Naphthoquinone Sulfonamides and Sulfonate Ester Derivatives as P2X7 Inhibitors.萘醌磺酰胺和磺酸盐酯衍生物作为 P2X7 抑制剂的合成、生物评价和分子建模研究。
Molecules. 2023 Jan 6;28(2):590. doi: 10.3390/molecules28020590.
10
Origin, distribution, and function of three frequent coding polymorphisms in the gene for the human P2X7 ion channel.人类P2X7离子通道基因中三种常见编码多态性的起源、分布及功能
Front Pharmacol. 2022 Nov 18;13:1033135. doi: 10.3389/fphar.2022.1033135. eCollection 2022.
本文引用的文献
1
Short-Term Dexamethasone in Sars-CoV-2 Patients.新冠病毒患者的短期地塞米松治疗
R I Med J (2013). 2020 Jun 19;103(6):39-43.
2
A rationale for targeting the P2X7 receptor in Coronavirus disease 19.靶向治疗 2019 冠状病毒病中 P2X7 受体的原理。
Br J Pharmacol. 2020 Nov;177(21):4990-4994. doi: 10.1111/bph.15138. Epub 2020 Jul 26.
3
Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage.中性粒细胞与淋巴细胞比值可预测 2019 冠状病毒病重症患者的早期病情。
J Transl Med. 2020 May 20;18(1):206. doi: 10.1186/s12967-020-02374-0.
4
Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation.重症监护病房中应对新型冠状病毒肺炎：血管功能障碍、血栓形成与炎症失调
Intensive Care Med. 2020 Jun;46(6):1105-1108. doi: 10.1007/s00134-020-06059-6. Epub 2020 Apr 28.
5
CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement.CD147 作为 COVID-19 治疗靶点：阿奇霉素和干细胞干预的建议作用。
Stem Cell Rev Rep. 2020 Jun;16(3):434-440. doi: 10.1007/s12015-020-09976-7.
6
Severe COVID-19 infection associated with endothelial activation.严重的2019冠状病毒病感染与内皮细胞激活有关。
Thromb Res. 2020 Jun;190:62. doi: 10.1016/j.thromres.2020.04.014. Epub 2020 Apr 15.
7
Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19.重症新型冠状病毒肺炎中肺血栓形成现象的病理学证据
J Thromb Haemost. 2020 Jun;18(6):1517-1519. doi: 10.1111/jth.14844.
8
Coronavirus disease 2019 (COVID-19): current status and future perspectives.新型冠状病毒病 2019（COVID-19）：现状和未来展望。
Int J Antimicrob Agents. 2020 May;55(5):105951. doi: 10.1016/j.ijantimicag.2020.105951. Epub 2020 Mar 29.
9
COVID-19: a fast evolving pandemic.新型冠状病毒肺炎：一场快速演变的大流行病。
Trans R Soc Trop Med Hyg. 2020 Apr 8;114(4):241-248. doi: 10.1093/trstmh/traa025.
10
Autopsy in suspected COVID-19 cases.疑似 COVID-19 病例的尸检。
J Clin Pathol. 2020 May;73(5):239-242. doi: 10.1136/jclinpath-2020-206522. Epub 2020 Mar 20.
Zotero 插件